Heart Failure
HF
Heart failure (HF) is a major emerging public health problem associated with increasing prevalence in the ageing population, high morbidity and mortality rates, and the challenges involved with patient management and healthcare costs.
The number of patients with heart failure worldwide increased from 33.5 million in 1990 to 64.3 million in 2017 and this number is projected to increase in the next decade.
Heart failure is a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormality that results in reduced cardiac output and/or elevated intracardiac pressures.
Inflammation, tissue damage and/or adverse tissue remodeling are the biological processes that lead to the development of chronic heart failure.
Heart Failure
hf
Heart failure (HF) is a major emerging public health problem associated with increasing prevalence in the ageing population, high morbidity and mortality rates, and the challenges involved with patient management and healthcare costs.
The number of patients with heart failure worldwide increased from 33.5 million in 1990 to 64.3 million in 2017 and this number is projected to increase in the next decade.
Heart failure is a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormality that results in reduced cardiac output and/or elevated intracardiac pressures.
Inflammation, tissue damage and/or adverse tissue remodeling are the biological processes that lead to the development of chronic heart failure.
Key HF Figures
Key HF Figures
Potential
Pentosan Polysulfate Sodium (PPS) has been investigated as a therapeutic agent targeting tissue remodelling in HFrEF in preclinical animal models (aortic banding and myocardial infarction animal models). In these models, PPS was shown to target ADAMTS-4, a key enzyme that degrades the extracellular matrix (ECM) component called versican, in myocardial tissue.
The mechanisms of action of PPS that are potentially relevant to the treatment of heart failure include:
- Reduction in the synthesis of ADAMTS-4 mRNA and protein
- Inhibition of adverse cardiac tissue remodeling evidenced by reduction in versican degradation
- Improved cardiac function
- Reduction in pro-inflammatory cytokines and inhibition of transcription factor activity such as NF-κB
Development milestones
A translational animal model of HFpEF using the ZSF-1 obese rats to confirm pilot data on the therapeutic effects of PPS is being performed in collaboration with the Center for Heart Failure Research & Institute for Experimental Research, at Oslo University.
For more information and updates, please see our ASX announcements.
Heart Failure
HF
Heart failure (HF) is a major emerging public health problem associated with increasing prevalence in the ageing population, high morbidity and mortality rates, and the challenges involved with patient management and healthcare costs.
The number of patients with heart failure worldwide increased from 33.5 million in 1990 to 64.3 million in 2017 and this number is projected to increase in the next decade.
Heart failure is a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormality that results in reduced cardiac output and/or elevated intracardiac pressures.
Inflammation, tissue damage and/or adverse tissue remodeling are the biological processes that lead to the development of chronic heart failure.
Heart Failure
hf
Heart failure (HF) is a major emerging public health problem associated with increasing prevalence in the ageing population, high morbidity and mortality rates, and the challenges involved with patient management and healthcare costs.
The number of patients with heart failure worldwide increased from 33.5 million in 1990 to 64.3 million in 2017 and this number is projected to increase in the next decade.
Heart failure is a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormality that results in reduced cardiac output and/or elevated intracardiac pressures.
Inflammation, tissue damage and/or adverse tissue remodeling are the biological processes that lead to the development of chronic heart failure.
Key HF Figures
Key HF Figures
Potential
Pentosan Polysulfate Sodium (PPS) has been investigated as a therapeutic agent targeting tissue remodelling in HFrEF in preclinical animal models (aortic banding and myocardial infarction animal models). In these models, PPS was shown to target ADAMTS-4, a key enzyme that degrades the extracellular matrix (ECM) component called versican, in myocardial tissue.
The mechanisms of action of PPS that are potentially relevant to the treatment of heart failure include:
- Reduction in the synthesis of ADAMTS-4 mRNA and protein
- Inhibition of adverse cardiac tissue remodeling evidenced by reduction in versican degradation
- Improved cardiac function
- Reduction in pro-inflammatory cytokines and inhibition of transcription factor activity such as NF-κB
Development milestones
A translational animal model of HFpEF using the ZSF-1 obese rats to confirm pilot data on the therapeutic effects of PPS is being performed in collaboration with the Center for Heart Failure Research & Institute for Experimental Research, at Oslo University.
For more information and updates, please see our ASX announcements.
